Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML)

A. Pigneux; M. Labopin; J. Maertens; C. Cordonnier; L. Volin; G. Socié; D. Blaise; C. Craddock; N. Milpied; U. Bacher; F. Malard; J. Esteve; A. Nagler; M. Mohty

doi:10.1038/leu.2015.143

Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML)

A. Pigneux
, M. Labopin
, J. Maertens
, C. Cordonnier
, L. Volin
, G. Socié
, D. Blaise
, C. Craddock
, N. Milpied
, U. Bacher
, F. Malard
, J. Esteve
, A. Nagler
, M. Mohty^*

^*Corresponding author for this work

Bordeaux University Hospital
Université de Bordeaux
Sorbonne Université
Université Pierre et Marie Curie
KU Leuven
Hôpital Henri Mondor
Helsinki University Hospital
Université Paris Cité
Institut Paoli Calmettes
University of Birmingham
Munich Leukemia Laboratory
Hospital Clinic Barcelona
Sheba Medical Center at Tel Hashomer

Research output: Contribution to journal › Article › peer-review

54 Scopus citations

Abstract

Acute myeloid leukemia (AML) with 11q23/MLL rearrangement (MLL-r AML) is allocated to the intermediate- or high-risk cytogenetic prognostic category depending on the MLL fusion partner. A more favorable outcome has been reported in patients receiving an allogeneic hematopoietic stem-cell transplantation (alloHSCT), but this has not been confirmed in large series. We analyzed the outcome of alloHSCT among adult patients reported to the Acute Leukemia Working Party between 2000 and 2010. We identified 159 patients with 11q23/MLL rearranged AML allografted in first complete remission (CR1, n=138) or CR2, mostly corresponding to t(9;11), t(11;19), t(6;11) and t(10;11) translocations. Two-year overall survival (OS), leukemia-free survival (LFS), relapse incidence and non-relapse mortality were 56±4%, 51±4%, 31±3% and 17±4%, respectively. The outcome differed according to 11q23/MLL rearrangement, being more favorable in patients with t(9;11) and t(11;19) compared with t(10;11) and t(6;11) (2-year OS: 64±6% and 73±10% vs 40±13% and 24±11%, respectively; P<0.0001). Multivariate analysis for OS identified t(6;11), t(10;11), age>40 years and CR2 as unfavorable features, whereas t(6;11), t(10;11), CR2 and the use of reduced-intensity conditioning regimen affected poorly the LFS. This study confirms the potential role of alloHSCT for adult patients with 11q23/MLL rearranged AML in CR1.

Original language	English
Pages (from-to)	2375-2381
Number of pages	7
Journal	Leukemia
Volume	29
Issue number	12
DOIs	https://doi.org/10.1038/leu.2015.143
State	Published - 1 Dec 2015
Externally published	Yes

Funding

Funders
ATERHIT

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/leu.2015.143

Cite this

Pigneux, A., Labopin, M., Maertens, J., Cordonnier, C., Volin, L., Socié, G., Blaise, D., Craddock, C., Milpied, N., Bacher, U., Malard, F., Esteve, J., Nagler, A., & Mohty, M. (2015). Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML). Leukemia, 29(12), 2375-2381. https://doi.org/10.1038/leu.2015.143

@article{4b43ef4ab4e3405295d5e1da3b077c47,

title = "Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML)",

abstract = "Acute myeloid leukemia (AML) with 11q23/MLL rearrangement (MLL-r AML) is allocated to the intermediate- or high-risk cytogenetic prognostic category depending on the MLL fusion partner. A more favorable outcome has been reported in patients receiving an allogeneic hematopoietic stem-cell transplantation (alloHSCT), but this has not been confirmed in large series. We analyzed the outcome of alloHSCT among adult patients reported to the Acute Leukemia Working Party between 2000 and 2010. We identified 159 patients with 11q23/MLL rearranged AML allografted in first complete remission (CR1, n=138) or CR2, mostly corresponding to t(9;11), t(11;19), t(6;11) and t(10;11) translocations. Two-year overall survival (OS), leukemia-free survival (LFS), relapse incidence and non-relapse mortality were 56±4\%, 51±4\%, 31±3\% and 17±4\%, respectively. The outcome differed according to 11q23/MLL rearrangement, being more favorable in patients with t(9;11) and t(11;19) compared with t(10;11) and t(6;11) (2-year OS: 64±6\% and 73±10\% vs 40±13\% and 24±11\%, respectively; P<0.0001). Multivariate analysis for OS identified t(6;11), t(10;11), age>40 years and CR2 as unfavorable features, whereas t(6;11), t(10;11), CR2 and the use of reduced-intensity conditioning regimen affected poorly the LFS. This study confirms the potential role of alloHSCT for adult patients with 11q23/MLL rearranged AML in CR1.",

author = "A. Pigneux and M. Labopin and J. Maertens and C. Cordonnier and L. Volin and G. Soci{\'e} and D. Blaise and C. Craddock and N. Milpied and U. Bacher and F. Malard and J. Esteve and A. Nagler and M. Mohty",

note = "Publisher Copyright: {\textcopyright} 2015 Macmillan Publishers Limited.",

year = "2015",

month = dec,

day = "1",

doi = "10.1038/leu.2015.143",

language = "אנגלית",

volume = "29",

pages = "2375--2381",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "12",

}

Pigneux, A, Labopin, M, Maertens, J, Cordonnier, C, Volin, L, Socié, G, Blaise, D, Craddock, C, Milpied, N, Bacher, U, Malard, F, Esteve, J, Nagler, A & Mohty, M 2015, 'Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML)', Leukemia, vol. 29, no. 12, pp. 2375-2381. https://doi.org/10.1038/leu.2015.143

TY - JOUR

T1 - Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML)

AU - Pigneux, A.

AU - Labopin, M.

AU - Maertens, J.

AU - Cordonnier, C.

AU - Volin, L.

AU - Socié, G.

AU - Blaise, D.

AU - Craddock, C.

AU - Milpied, N.

AU - Bacher, U.

AU - Malard, F.

AU - Esteve, J.

AU - Nagler, A.

AU - Mohty, M.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Acute myeloid leukemia (AML) with 11q23/MLL rearrangement (MLL-r AML) is allocated to the intermediate- or high-risk cytogenetic prognostic category depending on the MLL fusion partner. A more favorable outcome has been reported in patients receiving an allogeneic hematopoietic stem-cell transplantation (alloHSCT), but this has not been confirmed in large series. We analyzed the outcome of alloHSCT among adult patients reported to the Acute Leukemia Working Party between 2000 and 2010. We identified 159 patients with 11q23/MLL rearranged AML allografted in first complete remission (CR1, n=138) or CR2, mostly corresponding to t(9;11), t(11;19), t(6;11) and t(10;11) translocations. Two-year overall survival (OS), leukemia-free survival (LFS), relapse incidence and non-relapse mortality were 56±4%, 51±4%, 31±3% and 17±4%, respectively. The outcome differed according to 11q23/MLL rearrangement, being more favorable in patients with t(9;11) and t(11;19) compared with t(10;11) and t(6;11) (2-year OS: 64±6% and 73±10% vs 40±13% and 24±11%, respectively; P<0.0001). Multivariate analysis for OS identified t(6;11), t(10;11), age>40 years and CR2 as unfavorable features, whereas t(6;11), t(10;11), CR2 and the use of reduced-intensity conditioning regimen affected poorly the LFS. This study confirms the potential role of alloHSCT for adult patients with 11q23/MLL rearranged AML in CR1.

AB - Acute myeloid leukemia (AML) with 11q23/MLL rearrangement (MLL-r AML) is allocated to the intermediate- or high-risk cytogenetic prognostic category depending on the MLL fusion partner. A more favorable outcome has been reported in patients receiving an allogeneic hematopoietic stem-cell transplantation (alloHSCT), but this has not been confirmed in large series. We analyzed the outcome of alloHSCT among adult patients reported to the Acute Leukemia Working Party between 2000 and 2010. We identified 159 patients with 11q23/MLL rearranged AML allografted in first complete remission (CR1, n=138) or CR2, mostly corresponding to t(9;11), t(11;19), t(6;11) and t(10;11) translocations. Two-year overall survival (OS), leukemia-free survival (LFS), relapse incidence and non-relapse mortality were 56±4%, 51±4%, 31±3% and 17±4%, respectively. The outcome differed according to 11q23/MLL rearrangement, being more favorable in patients with t(9;11) and t(11;19) compared with t(10;11) and t(6;11) (2-year OS: 64±6% and 73±10% vs 40±13% and 24±11%, respectively; P<0.0001). Multivariate analysis for OS identified t(6;11), t(10;11), age>40 years and CR2 as unfavorable features, whereas t(6;11), t(10;11), CR2 and the use of reduced-intensity conditioning regimen affected poorly the LFS. This study confirms the potential role of alloHSCT for adult patients with 11q23/MLL rearranged AML in CR1.

UR - https://www.scopus.com/pages/publications/84951569594

U2 - 10.1038/leu.2015.143

DO - 10.1038/leu.2015.143

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 26082270

AN - SCOPUS:84951569594

SN - 0887-6924

VL - 29

SP - 2375

EP - 2381

JO - Leukemia

JF - Leukemia

IS - 12

ER -

Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML)

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this